Tilray Brands (TLRY) Capital Expenditures Growth (1y) (2018 - 2025)
Tilray Brands (TLRY) Capital Expenditures Growth (1y) (2018 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 32.28% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -38.20% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -15.72% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 32.98% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | -6.34% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -86.92% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -21.54% |
| 10 | Tilray Brands | 454.65 Mn | 394.45 Mn | 54.95 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2025 | -34.80% |
| Feb 28, 2025 | 51.28% |
| Nov 30, 2024 | -7.22% |
| Aug 31, 2024 | 62.24% |
| May 31, 2024 | -21.73% |
| Feb 29, 2024 | 1,011.79% |
| Nov 30, 2023 | 29.14% |
| Aug 31, 2023 | 38.40% |
| May 31, 2023 | 121.77% |
| Feb 28, 2023 | -81.43% |
| Nov 30, 2022 | -39.83% |
| Aug 31, 2022 | -81.61% |
| May 31, 2022 | 13.17% |
| Nov 30, 2021 | -52.60% |
| Aug 31, 2021 | 16.92% |
| May 31, 2021 | -89.78% |
| May 31, 2020 | -58.90% |
| Mar 31, 2020 | 102.84% |
| Sep 30, 2019 | 145.53% |
| Mar 31, 2019 | -29.86% |